Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is also used to treat persistent GBM and provide symptomatic relief, primarily by reducing vascular normalization-induced edema [8]. This evidence concerns the gene VEGFA and glioblastoma.